Table 1.
Demographic and clinicopathologic characteristics in the development cohort
| Variable | Value |
|---|---|
| Sex, n (%) | |
| Male | 132 (46.6) |
| Female | 151 (53.4) |
| Age, median (range) | 65.4 y (27.5–90.2 y) |
| Race/ethnicity, n (%) | |
| Caucasian | 215 (76.0) |
| Asian | 27 (9.5) |
| Black | 19 (6.7) |
| Hispanic | 21 (7.4) |
| Unknown | 1 (0.3) |
| Smoking status, n (%) | |
| Never-smoker | 64 (22.6) |
| Former smoker | 136 (48.1) |
| Current smoker | 82 (29.0) |
| Unknown | 1 (0.3) |
| Vital status, n (%) | |
| Alive | 172 (60.8) |
| Deceased | 111 (39.2) |
| Molecular platform, n (%) | |
| NGS | 218 (77.0) |
| PCRa | 55 (19.5) |
| Not done | 10 (3.5) |
| Molecular subtype, n (%) (n = 233) | |
| sTRU – EGFR (%) | 34 (14.6) |
| sPP – KRAS (%) | 43 (18.5) |
| sPI – TP53 (%) | 46 (19.7) |
| Co-mutation | 60 (25.8) |
| EGFR/TP53 | 26 (11.2) |
| KRAS/ TP53 | 34 (14.6) |
| Non-TRUPPPI | 21 (9.0) |
| No mutations detected by NGS | 29 (12.4) |
| FISH results, n (%) | |
| Negative | 250 (88.3) |
| Positive | 24 (8.5) |
| ALK | 16 (5.7) |
| ROS1 | 1 (0.4) |
| RET | 2 (0.7) |
| MET | 5 (1.8) |
| Indeterminate | 9 (3.2) |
| Aneuploidy | 193 (68.2) |
NGS Next-generation sequencing, PCR Polymerase chain reaction, sTRU Simplified terminal respiratory unit, sPP Simplified proximal-proliferative, sPI Simplified proximal-inflammatory, non-TRUPPPI Mutations in genes other than EGFR, KRAS, and TP53, FISH Fluorescence in situ hybridization
aSanger sequencing or pyrosequencing